1. Home
  2. ELWT vs VERU Comparison

ELWT vs VERU Comparison

Compare ELWT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ELWT

Elauwit Connection Inc.

N/A

Current Price

$7.05

Market Cap

50.6M

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.56

Market Cap

41.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELWT
VERU
Founded
2002
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.6M
41.7M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
ELWT
VERU
Price
$7.05
$2.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$12.00
$22.50
AVG Volume (30 Days)
57.7K
65.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
$167.76
N/A
Revenue Next Year
$22.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.11
$0.36
52 Week High
$8.25
$4.59

Technical Indicators

Market Signals
Indicator
ELWT
VERU
Relative Strength Index (RSI) 64.68 53.48
Support Level $4.26 $2.15
Resistance Level $8.15 $2.77
Average True Range (ATR) 0.74 0.16
MACD 0.10 0.01
Stochastic Oscillator 70.78 70.85

Price Performance

Historical Comparison
ELWT
VERU

About ELWT Elauwit Connection Inc.

Elauwit Connection Inc is a customer-centric service provider of broadband Internet networks for the multifamily and student housing property sectors across the United States. The company generates revenue from the following sources: network design and installation and internet network services. It provides service offering wholesale to REITs, property ownership groups, and property management companies, engaged in its target real estate sectors.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: